Essex Bio-Technology Limited: First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
HONG KONG, Feb 10, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that the first patient in the United States (US) was dosed in a global